Home > Research > Publications & Outputs > Incretin-based therapy for type 2 diabetes mell...

Electronic data

  • review_manuscript

    Accepted author manuscript, 927 KB, PDF document

    Available under license: CC BY-NC: Creative Commons Attribution-NonCommercial 4.0 International License

Links

Text available via DOI:

View graph of relations

Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases

Research output: Contribution to journalJournal article

Published

Standard

Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases. / Li, Yanwei; Li, Lin; Holscher, Christian.

In: Reviews in the Neurosciences, Vol. 27, No. 7, 10.2016, p. 689-711.

Research output: Contribution to journalJournal article

Harvard

APA

Vancouver

Author

Li, Yanwei ; Li, Lin ; Holscher, Christian. / Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases. In: Reviews in the Neurosciences. 2016 ; Vol. 27, No. 7. pp. 689-711.

Bibtex

@article{4aa2115afd4c4652b5d486257d53434b,
title = "Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases",
abstract = "Incretin hormones include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Due to their promising action on insulinotropic secretion and improving insulin resistance (IR), incretin-based therapies have become a new class of antidiabetic agents for the treatment of type 2 diabetes mellitus (T2DM). Recently, the links between neurodegenerative diseases and T2DM have been identified in a number of studies, which suggested that shared mechanisms, such as insulin dysregulation or IR, may underlie these conditions. Therefore, the effects of incretins in neurodegenerative diseases have been extensively investigated. Protease-resistant long-lasting GLP-1 mimetics such as lixisenatide, liraglutide, and exenatide not only have demonstrated promising effects for treating neurodegenerative diseases in preclinical studies but also have shown first positive results in Alzheimer’s disease (AD) and Parkinson’s disease (PD) patients in clinical trials. Furthermore, the effects of other related incretin-based therapies such as GIP agonists, dipeptidyl peptidase-IV (DPP-IV) inhibitors, oxyntomodulin (OXM), dual GLP-1/GIP, and triple GLP-1/GIP/glucagon receptor agonists on neurodegenerative diseases have been tested in preclinical studies. Incretin-based therapies are a promising approach for treating neurodegenerative diseases.",
keywords = "Alzheimer’s disease, DPP-IV inhibitors, glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, incretin, insulin resistance, Parkinson’s disease, type 2 diabetes mellitus",
author = "Yanwei Li and Lin Li and Christian Holscher",
year = "2016",
month = "10",
doi = "10.1515/revneuro-2016-0018",
language = "English",
volume = "27",
pages = "689--711",
journal = "Reviews in the Neurosciences",
issn = "0334-1763",
publisher = "WALTER DE GRUYTER GMBH",
number = "7",

}

RIS

TY - JOUR

T1 - Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases

AU - Li, Yanwei

AU - Li, Lin

AU - Holscher, Christian

PY - 2016/10

Y1 - 2016/10

N2 - Incretin hormones include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Due to their promising action on insulinotropic secretion and improving insulin resistance (IR), incretin-based therapies have become a new class of antidiabetic agents for the treatment of type 2 diabetes mellitus (T2DM). Recently, the links between neurodegenerative diseases and T2DM have been identified in a number of studies, which suggested that shared mechanisms, such as insulin dysregulation or IR, may underlie these conditions. Therefore, the effects of incretins in neurodegenerative diseases have been extensively investigated. Protease-resistant long-lasting GLP-1 mimetics such as lixisenatide, liraglutide, and exenatide not only have demonstrated promising effects for treating neurodegenerative diseases in preclinical studies but also have shown first positive results in Alzheimer’s disease (AD) and Parkinson’s disease (PD) patients in clinical trials. Furthermore, the effects of other related incretin-based therapies such as GIP agonists, dipeptidyl peptidase-IV (DPP-IV) inhibitors, oxyntomodulin (OXM), dual GLP-1/GIP, and triple GLP-1/GIP/glucagon receptor agonists on neurodegenerative diseases have been tested in preclinical studies. Incretin-based therapies are a promising approach for treating neurodegenerative diseases.

AB - Incretin hormones include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Due to their promising action on insulinotropic secretion and improving insulin resistance (IR), incretin-based therapies have become a new class of antidiabetic agents for the treatment of type 2 diabetes mellitus (T2DM). Recently, the links between neurodegenerative diseases and T2DM have been identified in a number of studies, which suggested that shared mechanisms, such as insulin dysregulation or IR, may underlie these conditions. Therefore, the effects of incretins in neurodegenerative diseases have been extensively investigated. Protease-resistant long-lasting GLP-1 mimetics such as lixisenatide, liraglutide, and exenatide not only have demonstrated promising effects for treating neurodegenerative diseases in preclinical studies but also have shown first positive results in Alzheimer’s disease (AD) and Parkinson’s disease (PD) patients in clinical trials. Furthermore, the effects of other related incretin-based therapies such as GIP agonists, dipeptidyl peptidase-IV (DPP-IV) inhibitors, oxyntomodulin (OXM), dual GLP-1/GIP, and triple GLP-1/GIP/glucagon receptor agonists on neurodegenerative diseases have been tested in preclinical studies. Incretin-based therapies are a promising approach for treating neurodegenerative diseases.

KW - Alzheimer’s disease

KW - DPP-IV inhibitors

KW - glucagon-like peptide-1

KW - glucose-dependent insulinotropic polypeptide

KW - incretin

KW - insulin resistance

KW - Parkinson’s disease

KW - type 2 diabetes mellitus

U2 - 10.1515/revneuro-2016-0018

DO - 10.1515/revneuro-2016-0018

M3 - Journal article

VL - 27

SP - 689

EP - 711

JO - Reviews in the Neurosciences

JF - Reviews in the Neurosciences

SN - 0334-1763

IS - 7

ER -